Drugs / 124I-Metaiodobenzylguanidine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01583842 | Apr 2013 → Feb 2021 | neuroblastoma | Miguel Pampaloni | Terminated | No outcome recorded Stop: Business |
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT02043899 | Feb 2014 → Oct 2020 | neuroblastoma | Cancer Research UK | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 124I-Metaiodobenzylguanidine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01583842 ↗ |
| Known as | \[124I\]mIBG | “new novel PET tracer (called \[124I\]mIBG) can detect as many or more sites of neuroblastoma” NCT02043899 ↗ |
| Modality | Diagnostic / imaging agent | “diagnostic imaging dose of 124I-MIBG” NCT01583842 ↗ |
| Route | Intravenous | “Single intravenous administration of \[124I\]mIBG Solution for Injection” NCT02043899 ↗ |